ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2609

The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated up to 19 Months with Tofacitinib

Kevin L Winthrop1, Ann Wouters2, Ernest H. Choy3,4, Chudy Nduaka2, Staci Abramsky2, Pinaki Biswas2, Lisy Wang5, Jennifer Hodge2, Irina Lazariciu6, Koshika Soma2, Christopher F Mojcik2 and William F.C Rigby7, 1Oregon Health and Sciences University, Portland, OR, 2Pfizer Inc, New York, NY, 3CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Great Britain, 4CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, 5Pfizer Inc, Groton, CT, 6Quintiles, Saint-Laurent, QC, Canada, 7Geisel School of Medicine at Dartmouth, Lebanon, NH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Rheumatoid arthritis (RA), Safety, Tofacitinib and vaccines

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for herpes zoster (HZ), and vaccination is recommended in patients over the age of 50 years, prior to starting biologics or tofacitinib, an oral Janus kinase inhibitor for the treatment of RA. In immunocompetent adults aged ≥50 years zoster vaccine has shown 70% efficacy (in 50–59 year-olds over 1.3 years) to 51% efficacy (in ≥60-year-olds over 4.9 years) for the prevention of HZ.1 We previously reported the safety and immunogenicity of live zoster vaccine in RA patients on background methotrexate (MTX) before initiating tofacitinib or placebo.2 Briefly, patients with RA who started 3 months of treatment with tofacitinib after zoster vaccination generated immunity to varicella zoster virus (VZV) similar to placebo-treated recipients. Furthermore their VZV immunity at Week 6 post-vaccination was comparable with immunity in healthy people aged 50 years and older.2 However, the long-term effectiveness of the vaccine in this setting is unknown.

Methods: From a prior cohort of patients (n=100) given zoster vaccine and then randomized 2 to 3 weeks later to tofacitinib 5 mg BID, or placebo, for 12 weeks (A3921237 [NCT02147587]), we evaluated the incidence of HZ post-vaccination during long-term tofacitinib use. At 14 weeks post-vaccination, patients joining the long-term extension (LTE) study (ORAL Sequel; [NCT00413699]) initiated open-label treatment with tofacitinib 5 mg or 10 mg BID at the discretion of the investigator. HZ cases after tofacitinib exposure up to 19 months were evaluated. Among HZ cases, we described and compared measures of VZV-specific immunity with average immunity after live zoster vaccination.

Results: 112 pts were randomized to placebo (n=57) or tofacitinib 5 mg BID (n=55), and 100 of these patients continued to receive tofacitinib in the ORAL Sequel study. The overall exposure to tofacitinib ranged from 9 to 19 months. Two HZ cases occurred, one at 202 days (219 days from vaccination) and another at 267 days (281 days from vaccination) after tofacitinib start. Both were monodermatomal and resolved with antiviral therapy. Review of immunogenicity data at 6 weeks post-vaccination revealed that Case #1 had undetectable ELISPOT measures at baseline and at Week 6 post-vaccination. Case #2 responded adequately to vaccination by both IgG and ELISPOT measures, but had much lower than average post-vaccination IgG levels (Table 1).

Conclusion: The observed HZ incidence rate after vaccination was low among this cohort of tofacitinib-treated patients. Zoster vaccination prior to tofacitinib start is effective at boosting IgG levels and cell-mediated immunity towards VZV, although individuals with poor vaccine response may be more likely to develop HZ. Reference: 1. Hales CM et al. MMWR Morb Motal Wkly Rep 2014; 63:729-31. 2. Winthrop K et al. Arthritis Rheumatol 2015; 67 (suppl 10): Abstract 12L.


Disclosure: K. L. Winthrop, Pfizer Inc, 2; A. Wouters, Pfizer Inc, 1,Pfizer Inc, 3; E. H. Choy, None; C. Nduaka, Pfizer Inc, 1,Pfizer Inc, 3; S. Abramsky, Pfizer Inc, 1,Pfizer Inc, 3; P. Biswas, Pfizer Inc, 1,Pfizer Inc, 3; L. Wang, Pfizer Inc, 1,Pfizer Inc, 3; J. Hodge, Pfizer Inc, 1,Pfizer Inc, 3; I. Lazariciu, Pfizer Inc, 5,Quintiles, 3; K. Soma, Pfizer Inc, 3,Pfizer Inc, 1; C. F. Mojcik, Pfizer Inc, 1,Pfizer Inc, 3; W. F. C. Rigby, None.

To cite this abstract in AMA style:

Winthrop KL, Wouters A, Choy EH, Nduaka C, Abramsky S, Biswas P, Wang L, Hodge J, Lazariciu I, Soma K, Mojcik CF, Rigby WFC. The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated up to 19 Months with Tofacitinib [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-effectiveness-of-zoster-vaccine-in-ra-patients-subsequently-treated-up-to-19-months-with-tofacitinib/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effectiveness-of-zoster-vaccine-in-ra-patients-subsequently-treated-up-to-19-months-with-tofacitinib/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences